These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 39443907)

  • 21. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
    Meir P; Taylor L; Soares JC; Meyer TD
    J Affect Disord; 2023 Feb; 323():748-754. PubMed ID: 36535547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
    Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M
    J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
    Calder AE; Hasler G
    J Affect Disord; 2024 Nov; 365():258-264. PubMed ID: 39168165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic research at a crossroads.
    Armstrong SB; Davis AK
    Science; 2024 Sep; 385(6715):1255. PubMed ID: 39298596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment.
    Edelsohn GA; Sisti D
    Perspect Biol Med; 2023; 66(1):129-144. PubMed ID: 38662012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychedelic-assisted therapies: The past, and the need to move forward responsibly.
    Gardner J; Carter A; O'Brien K; Seear K
    Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?
    Mohamed A; Touheed S; Ahmed M; Hor M; Fatima S
    Cureus; 2022 Oct; 14(10):e30919. PubMed ID: 36465766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelic Drug Legislative Reform and Legalization in the US.
    Siegel JS; Daily JE; Perry DA; Nicol GE
    JAMA Psychiatry; 2023 Jan; 80(1):77-83. PubMed ID: 36477830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
    Rosa WE; Sager Z; Miller M; Bernstein I; Doerner Rinaldi A; Addicott K; Ljuslin M; Adrian C; Back AL; Beachy J; Bossis AP; Breitbart WS; Cosimano MP; Fischer SM; Guss J; Knighton E; Phelps J; Richards BD; Richards WA; Tulsky JA; Williams MT; Beaussant Y
    J Palliat Med; 2022 Aug; 25(8):1273-1281. PubMed ID: 35285721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.